Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36877893

First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2023 Apr 20
First author
Burtness B

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332.
    note
    Source null
    related pmid
    36473143
    relationship
    Comment on

Authors and identifiers

  1. name
    Burtness B
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Burtness B
    type
    Author
bibliography ids
  1. nci-bib-566e3b2a038c50a738b7262b
book metadata
content sha256
c8bd13d99cfa1e665ba90a8b7534f4bec4bb8ec24a37e96f59fbb44f69e0a069
document type
citation
dois
  1. 10.1200/JCO.22.02349
electronic publication date
display
2023 Mar 6
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:36877893
immutable id
pubmed:36877893@c8bd13d99cfa1e665ba90a8b7534f4bec4bb8ec24a37e96f59fbb44f69e0a069
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
12
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
2134-2137
volume
41
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332.
    note
    Source null
    related pmid
    36473143
    relationship
    Comment on
outcomes validated
false
pmid
36877893
provenance
batch id
d370e99271168e8a8a13
provider
NCBI PubMed ESummary
record sha256
6cb65a83a6961f10e6c22ad3b02f365280b08d7f0da7fbd7077c6b20a5dcfd35
response sha256
f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
retrieved at
2026-09-09T23:48:13.005737+00:00
publication date
display
2023 Apr 20
precision
day
year
2023
publication types
  1. Editorial
  2. Comment
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36877893/
title
First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?

Preserved source evidence · Not medical advice